{"prompt": "['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', 'ICH', 'International Council for Harmonization (formerly the International', 'Conference on Harmonization)', 'ID', 'Identification', 'IEC', 'Independent Ethics Committee', 'IFN-y', 'Interferon- Y', 'IL', 'Interleukin', 'IMP', 'Investigational Medicinal Product', 'IRB', 'Institutional Review Board', 'LOCF', 'Last Observation Carried Forward', 'LPO', 'Last Patient Out', 'MACE', 'Major Adverse Cardiac Events', 'MBO', '(Model) Professional Code for Physicians in Germany', 'MCP-1', 'Monocyte chemoattractant protein-1 (= CCL2)', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'mRNA', 'Messenger Ribonucleic Acid', 'n,N', 'Number', 'PASI', 'Psoriasis Area and Severity Index', 'PDE/PDE4', 'Phosphodiesterase / Phosphodiesterase 4', 'PGA', 'Physician Global Assessment', 'PP', 'Per Protocol (set)', 'PPP', 'Palmoplantar pustulosis', 'PPPASI', 'Palmoplantar Pustulosis Psoriasis Area and Severity Index', 'PPPASI 50/75', '50% / 75% decrease in PPPASI', 'PsA', 'Psoriasis Arthritis', 'PT', 'Preferred Term', 'PUVA', 'Psoralen plus ultraviolet A radiation', 'qPCR', 'Real-time Polymerase Chain Reaction on reverse transcribed', 'mRNA', 'RMP', 'Risk Management plan', 'SAE', 'Serious Adverse Event', 'SAP', 'Statistical Analysis Plan', 'SOC', 'System Organ Class', 'SOP', 'Standard Operating Procedure', 'sP-selectin', 'Soluble P-selectin', 'ThX', 'T Helper Cell X', 'Page 18 of 75']['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', 'TNF', 'Tumor Necrosis Factor', 'TEAE', 'Treatment emergent AE', 'ULN', 'Upper limit of normal', 'UVB', 'Ultraviolet B', 'V', 'Visit', 'VAS', 'Visual Analogue Scale', 'WHO', 'World Health Organization', 'Page 19 of 75']['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', 'Definitions', 'Baseline', 'Data collected for all patients at the beginning of a clinical', 'study before any study treatment. These data include', 'demographics, such as age and gender, and study-specific', 'measures.', 'Eligible Patient', 'Any potential participant who upon entrance into the treatment', 'phases of the study meets all of the inclusion criteria and none', 'of the exclusion criteria set forth in the protocol and had signed', 'a valid Ethics Committee (EC) approved informed consent', 'form.', 'End of Study', '/', 'Study Final date on which data is collected (i.e. date of the last visit', 'Completion Date', 'of the last patient).', 'Screening', 'Evaluation of patients for participation in a clinical study', 'according to inclusion and exclusion criteria.', 'Page 20 of 75']\n\n###\n\n", "completion": "END"}